The EU Falsified Medicines Directive (FMD) requires pharmaceutical manufacturers to serialize their products and to provide secondary product packaging with an anti-tampering device. Primary containers or devices such as pens and autoinjectors for self-medication, however, are not included in these requirements yet. Schreiner MediPharm has developed an NFC-Label for autoinjectors that enables digital tamper evidence on primary packaging and makes it possible for pharmaceutical manufacturers to close this risk gap.